Compare Ascendis Pharma A/S (ASND) vs Philip Morris International Inc. (PM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Philip Morris International Inc. — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Philip Morris International Inc. trades at $182.02 (market cap $283.07B). The key difference: Philip Morris International Inc. is far larger — about 16× Ascendis Pharma A/S's market cap, and Philip Morris International Inc. pays a 3.24% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | PM | |
|---|---|---|
Market Cap | $17.74B | $283.07B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $191.86 |
52-Week Low | $163.32 | $144.33 |
Enterprise Value | $18.11B | $329.56B |
Dividend Yield | — | 3.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Philip Morris International (PM) trades at $181.62, up 0.25% today, near the analyst consensus price target of $194. The stock shows a bullish technical trend with support at $179 and resistance at $185. Recent Q1 2026 earnings beat expectations at $1.96 EPS versus $1.86, though Q4 2025 missed. Revenue grew to $40.65B in 2025 with a strong net margin of 26.74%. The company announced a $1.47 dividend payable July 20, 2026, but cut its 2026 profit forecast due to a $500M impairment and cost pressures.
Outlook remains positive with 68% analyst buy ratings, but risks include rising illicit cigarette trade in Europe, currency volatility, and consumer spending constraints. The stock offers value with a P/E of 25.57 and stable cash flows, though high debt levels and regulatory challenges require monitoring for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
